A Single Arm, Open-Label Study To Evaluate The Safety, Tolerability And Preliminary Efficacy Of NM-IL-12 (rHuIL‐12) In Patients With Cutaneous T Cell Lymphoma (CTCL) Undergoing Low Dose Total Skin Electron Beam Therapy (TSEBT)

Trial Profile

A Single Arm, Open-Label Study To Evaluate The Safety, Tolerability And Preliminary Efficacy Of NM-IL-12 (rHuIL‐12) In Patients With Cutaneous T Cell Lymphoma (CTCL) Undergoing Low Dose Total Skin Electron Beam Therapy (TSEBT)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs NMIL 12 1 (Primary)
  • Indications Cutaneous T cell lymphoma
  • Focus Adverse reactions
  • Sponsors Neumedicines
  • Most Recent Events

    • 06 Dec 2016 Results (n=6) assessing safety and efficacy presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 14 Jan 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 08 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top